October 20, 2022
...

Hereditary amyloidosis is a life-threatening disorder that can lead to peripheral neuropathy and heart failure. Early diagnosis and treatment of hereditary amyloidosis can provide a normal quality of life and lifespan for your patients. This new in-house test will be performed at our main laboratory for prompt results and is complementary to HNL Genomics Cardiology offerings.

The TTR test is a Sanger sequencing test that detects pathogenic variants in the TTR gene which cause hereditary transthyretin amyloidosis. These pathogenic variants change the structure of the TTR protein leading to the progressive buildup of amyloid protein in the body's organs, including the heart, kidneys, eyes, and gastrointestinal tract.

Benefits

Use this test to pursue pharmacotherapies designed specifically for individuals with pathogenic TTR variants. Results provide valuable family medical history information that allow family members to pursue testing. If positive for a pathogenic variant, patients and family members may obtain an early diagnosis or be monitored for signs and symptoms before they occur.

Providers suspecting hereditary transthyretin amyloidosis can order this test easily in EPIC using code C7001. Our genetic testing experts are available to assist with any questions. Compared to three weeks with competitors, the turnaround time for our TTR test is just 7-14 days. Results are available in EPIC.

Test Summary

  • Transthyretin amyloidosis
  • Detects variants in TTR gene
  • EPIC Code C7001
  • Turnaround Time: 7-14 days

Time matters to your patients. HNL Lab Medicine delivers patient results quickly and conveniently. Take advantage of our newly available TTR test to provide superior patient care. For inquiry or assistance, please contact customer care at 877-402-4221. For clinical information or to discuss a patient, providers may also contact HNL Genomics at 484-244-2900.

The American Medical Association (AMA) Current Procedural Terminology (CPT) codes published by HNL Lab Medicine are guidelines and are intended for informational purposes only. CPT coding is the exclusive responsibility of the billing entity. HNL Lab Medicine strongly recommends confirmation of CPT codes with third-party payors and/or the AMA. We assume no responsibility for billing errors due to reliance upon CPT codes provided by HNL Lab Medicine.

News

October 28, 2022

Non-Hodgkin Lymphoma FISH Panel Now Available

B-cell lymphoma is a large group of heterogenous disorders and comprises a majority of non-Hodgkin lymphomas.
Read More
October 20, 2022

Genetic testing for Familial Transthyretin Amyloidosis (TTR) NOW AVAILABLE In-House

Hereditary amyloidosis is a life-threatening disorder that can lead to peripheral neuropathy and heart failure.
Read More
August 08, 2022

Familial hypercholesterolemia (FH)

Familial hypercholesterolemia (FH) is a genetic disorder that increases the likelihood of having coronary heart disease at a younger age. Learn about how to determine if you have hypercholesterolemia and what actions you can take to create better outcomes!

Read More
April 11, 2022

Genome Sequencing: A Vital Tool Used in Identifying and Tracking New COVID-19 Variants

Genome sequencing is reading or decoding the complete genetic information i.e. “Genome” of an organism that is encrypted in the form of a very long string called DNA made up of 4 letters, A, T, G, and C. The genome of an organism essentially determines their physical characteristics and ...
Read More
March 03, 2022

The Effect of Genetics on Individual Heart Health: Early Identification of FH Variations to Optimize Treatment

Test must be ordered by a Physician.

Familial hypercholesterolemia (FH) is a genetic disorder that is characterized by abnormally high blood levels of low-density lipoprotein (LDL) cholesterol, sometimes referred to as "bad cholesterol". This condition affects an estimated 1 in 250 people, and increases the likelihood of developing cardiovascular disease. In fact, FH is estimated to be the cause of 2-3% of heart attacks in individuals younger than age 60.

Read More